Warren Buffett's Successor Greg Abel Just Broke This 13-Quarter Streak at Berkshire Hathaway. Could This Be a Turning Point for the Stock Market?

Berkshire Hathaway ended Warren Buffett’s 13-quarter streak of selling more stock than it bought after Greg Abel and Ted Weschler combined roughly $16 billion of equity purchases with the $9.7 billion OxyChem acquisition, offsetting more than $24 billion of equity sales. Even so, Berkshire still appears cautious: it bought back only $238 million of stock despite a lower price-to-book ratio, and Buffett said the current environment is not ideal for deploying cash. The article suggests Berkshire’s capital deployment is improving, but not enough to signal a broad shift to aggressive buying.

Analysis

The meaningful signal here is not that Berkshire finally bought more than it sold; it is that the company’s capital allocation bar has shifted from “defensive hoarding” to “selective redeployment,” and that typically happens late in a cycle when high-quality assets are scarce but not absent. That tends to favor situations where a large, patient buyer can force value realization through asset separations or balance-sheet simplification, which is exactly why OXY stands out more than the broad market tape. OXY likely benefits twice: first from monetization of a non-core asset, then from reduced overhang as Berkshire implicitly validates the asset pool and capital structure.

The bigger second-order read-through is negative for beta-sensitive growth and tech names with no margin of safety. If Berkshire’s preferred hunting ground is still thin, the opportunity set in large-cap equities is probably less attractive than consensus assumes, and that argues for a more cautious stance on crowded quality/growth exposures rather than a pro-cyclical “Buffett is buying again” interpretation. The fact that buybacks remain minimal despite a softer stock-price-to-book signal suggests management may still think reported book understates true intrinsic value, which weakens the case for chasing BRK.B on headline capital-return optics alone.

For the next 1-3 quarters, the key catalyst is whether Berkshire’s deployment pattern persists after the one-off portfolio reshuffling from personnel changes. If buying remains selective and repurchases stay muted, the market should treat this as confirmation that attractive public equity opportunities are still scarce, not as an all-clear for risk assets. The contrarian setup is that the market may be overreacting to the return of net buying in Berkshire’s reported flow, when the real lesson is that deployable capital is still being rationed into only a handful of situations with unusually clear edge.

Key Decisions for Investors

• Long OXY vs short XLE or a broad energy basket for 1-3 months: thesis is idiosyncratic value-unlocking and balance-sheet cleanup at OXY should outperform commodity beta; stop if crude weakens sharply or Berkshire stops supporting the name.
• Avoid adding to long-duration growth exposure into the next 1-2 quarters where Berkshire-style disciplined capital allocation is not expanding; prefer a market-neutral pair long value/cash-flow names vs short high-multiple software/tech where valuation is least protected.
• For BRK.B holders, trim upside chase and instead sell covered calls 3-6 months out: implied vol should remain subdued while the stock lacks a clear catalyst for multiple expansion unless buybacks accelerate materially.
• Use any post-earnings or market-wide pullback to build positions in companies with identifiable self-help/M&A catalysts rather than index beta; Berkshire’s behavior suggests the best risk/reward is in special situations, not passive large-cap exposure.